Vai al contenuto principale

Laboratorio Diabetologia e Malattia del Ricambio

 

Resposabile: Prof. Roberto Gambino 

  • Ricerca di base e clinica nel campo delle malattie metaboliche, finanziata con risorse universitarie;
  • Didattica di Biochimica Clinica nei corsi di laurea in Medicina e Chirurgia, Biotecnologie Mediche e Laurea triennale professionalizzante;
  • Indagini diagnostiche per attività assistenziale con esecuzione di test diagnostici di secondo livello per gli Ambulatori di Diabetologia, per il “Centro per lo Studio delle Dislipidemie”, nonché per numerose Aziende Ospedaliere.

  • Musso G, Sircana A, Saba F, Cassader M, Gambino R. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. Plos Med 2020, 17(12): 1-31, e1003461
  • Musso G, Saba F, Cassader M, Gambino R. Diabetic ketoacidosis with SGLT2 inhibitors. British Medical Journal, 2020, 371: m4147.
  • Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. Musso G, Cassader M, Paschetta E, Gambino R. Gastroenterology. 2018 Aug;155(2):282-302.e8. doi: 10.1053/j.gastro.2018.06.031. Epub 2018 Jun 12. Review.
  • MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Musso G, Cassader M, De Michieli F, Paschetta E, Pinach S, Saba F, Bongiovanni D, Framarin L, Berrutti M, Leone N, Corvisieri S, Parente R, Molinaro F, Sircana A, Bo S, Gambino R. Hum Mol Genet. 2017 May 1;26(9):1747-1758. doi: 10.1093/hmg/ddw400. PMID: 29906416
  • TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. Musso G, Cipolla U, Cassader M, Pinach S, Saba F, De Michieli F, Paschetta E, Bongiovanni D, Framarin L, Leone N, Berrutti M, Rosina F, Corvisieri S, Molinaro F, Sircana A, Gambino R. J Lipid Res. 2017 Jun;58(6):1221-1229. doi: 10.1194/jlr.M075028. Epub 2017 Feb 27. PMID: 28242789.

  • Trial Clinico: Safety and efficacy of phytosomial curcumin in non-alcoholic steatohepatitis (NASH): a doubleblind, randomized, placebo-controlled trial. 25/05/2018 – 30/12/2022, N°40834, ISRCTN27793187, DOI 10.1186/ISRCTN27793187
  • Progetto PRIN 2017- Prot. 20174FHBWR: 2019-2022
  •  
  • PRIN 2010-2011 “Impatto di alimenti funzionali e/o nutraceutici contenenti polifenoli sul metabolismo energetico e glico-lipidico, l'infiammazione subclinica, l'espressione genica e le modificazioni epigenetiche in modelli sperimentali e nell'uomo”. (Prot. 2010JCWWKM_006;)
  • Anno 2010: Health research project of the region Piedmon “Effects of resveratrol on inflammation in type 2 diabetic patients. A double-blind randomised controlled trial”. (RF-2010-2313155)
  • Ex 60% anno 2021: Quorum sensing alkyl quinolones molecules, lipid profile and liver dysfunction in septic shock patients with AKI undergoing renal replacement therapy.
  • Ex 60% anno 2020: Serum Lumican Levels and Liver hystology in patients with NAFLD /NASH.
  • Ex 60% anno 2019: Evaluation of serum cysteine-rich protein 61 levels in patients with NAFLD before and after Curcumin Treatment.
  • Ex 60% anno 2018: Fibroblast Growth Factor 21 (FGF-21) in Subjects with NAFLD before and after Curcumin Treatment
  • Ex 60% anni 2016-2017: Impact of Toll-like receptor (TLR)-4 polymorphisms on incretin response to acute, nutrient-induced inflammation in NAFLD.
  • Ex 60% anno 2015: Interaction of endotoxemia with TLR-4 polymorphisms in determining NAFLD and diabetes.
  • Ex 60% anno 2014: Curcumin efficacy in the management of Non-Alcoholic Fatty Liver Disease (NAFLD).
  • Ex 60% anno 2013: “Effect of nonalcoholic fatty liver disease on cardiovascular risk in prehypertensive nonobese non-diabetic subjects without metabolic syndrome”.

  

Ultimo aggiornamento: 28/04/2023 15:25
Non cliccare qui!